| Hazard Information | Back Directory | [Uses]
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer[1]. | [in vivo]
Ontuxizumab (50 mg/kg; i.v., 5 doses daily for 5 consecutive days) shows antitumor effects in human CD248 knock-in mice[1]. | Animal Model: | Human CD248 knock-in mice[1] | | Dosage: | 50 mg/kg | | Administration: | Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days | | Result: | Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes.
|
| [References]
[1] Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015 Sep 22;6(28):25429-40. DOI:10.18632/oncotarget.4559 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|